12 Things Cardiologists Think Hospitalists Need to Know
12 Things Cardiologists Think Hospitalists Need to Know
The introduction of dabigatran and rivaroxaban (and, perhaps soon, apixaban) to the array of anticoagulant therapies brings a new slate of considerations for hospitalists, Dr. Harold says.
"For the majority of these, there's no specific way to reverse the anticoagulant effect in the event of a major bleeding event," he says. "There's no simple antidote. And the effect can last up to 12 to 24 hours, depending on the renal function. This is what the hospitalist will be called to deal with: bleeding complications in patients who have these newer anticoagulants on board."
Dr. Fonarow says that the new CHA2DS2-VASc score has been found to do a better job than the traditional CHADS2 score in assessing afib stroke risk.
11) Beware the Idiosyncrasies of New Anticoagulants
The introduction of dabigatran and rivaroxaban (and, perhaps soon, apixaban) to the array of anticoagulant therapies brings a new slate of considerations for hospitalists, Dr. Harold says.
"For the majority of these, there's no specific way to reverse the anticoagulant effect in the event of a major bleeding event," he says. "There's no simple antidote. And the effect can last up to 12 to 24 hours, depending on the renal function. This is what the hospitalist will be called to deal with: bleeding complications in patients who have these newer anticoagulants on board."
Dr. Fonarow says that the new CHA2DS2-VASc score has been found to do a better job than the traditional CHADS2 score in assessing afib stroke risk.
Source...